GSK’s licensed B7-H3 antibody-drug conjugate Ris-Rez delivered median survival of 18.5 months versus 10.3 months with topotecan in a Chinese Phase 3 study, strengthening the company’s case for global development.
Samsung Biologics adds a $262 million manufacturing deal through 2033 as its capacity, acquisitions and global CDMO ambitions expand.
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Hansoh Pharmaceutical Group Co., Ltd. has reported that risvutatug rezetecan, also known as Ris-Rez or HS-20093, significantly improved overall survival in the pivotal Phase 3 ARTEMIS-008 trial involving Chinese patients with advanced or relapsed small-cell lung cancer following platinum-based treatment. The B7-H3-directed antibody-drug conjugate was compared with topotecan and also produced a consistent benefit in
Sino Biopharmaceutical Limited has secured two respiratory medicine transactions involving AstraZeneca PLC and GSK plc, strengthening both its out-licensing and China commercialization strategy. Its subsidiary Chia Tai Tianqing Pharmaceutical Group granted AstraZeneca exclusive rights outside China to develop, manufacture and commercialize TQC3721, an investigational PDE3/4 inhibitor for chronic respiratory disease, while separately obtaining mainland China
The first United States-approved oral carbapenem could replace intravenous therapy for selected complicated urinary tract infections, but stewardship, four-times-daily dosing and resistance risks will constrain its use.
Myriad Genetics secures FDA approval for MyChoice CDx in ovarian cancer. Discover how HRD testing could reshape PARP inhibitor treatment decisions.
Explore what the Bora Pharmaceuticals and GSK manufacturing deal reveals about long-term supply strategy and CDMO market shifts. Read the full analysis.
GSK plc has received regulatory approval from China’s National Medical Products Administration (NMPA) to market Trelegy Ellipta, a once-daily inhaled combination of fluticasone furoate, umeclidinium, and vilanterol, for the treatment of adult patients with uncontrolled asthma. This decision expands Trelegy Ellipta’s label beyond its existing indication in chronic obstructive pulmonary disease (COPD), making it the